NCT03634982 is a Phase 1 clinical trial of RMC-4630 in Solid Tumors, sponsored by Revolution Medicines, Inc..

Who is sponsoring NCT03634982?

NCT03634982 is sponsored by Revolution Medicines, Inc..

What drugs are being tested in NCT03634982?

Interventions in NCT03634982: RMC-4630.

What condition does NCT03634982 study?

NCT03634982 studies Solid Tumors.

Is NCT03634982 still recruiting?

NCT03634982 is currently status unknown. Last updated 1 September 2022.

Last reviewed 2022-09-01 · How we verify

NCT03634982

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Status unknown Phase 1 Last updated 1 September 2022

What this trial tests

Phase 1 trial testing RMC-4630 in Solid Tumors in 133 participants. Status unknown.

Timeline

28 September 2018

Primary endpoint
31 March 2023

31 May 2023

Quick facts

Lead sponsor	Revolution Medicines, Inc.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	133
Start date	28 September 2018
Primary completion	31 March 2023
Estimated completion	31 May 2023
Sites	12 locations across United States

Drugs / interventions tested

RMC-4630 — full drug profile →

Conditions studied

Solid Tumors — all drugs for Solid Tumors →

Sponsor

Revolution Medicines, Inc. — full company profile →

Who can join

18 and older, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors and to identify the recommended Phase 2 dose (RP2D).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

RAS-targeted therapies: is the undruggable drugged?
Moore AR, Rosenberg SC, McCormick F, Malek S. · · 2020 · cited 832× · PMID 32528145 · DOI 10.1038/s41573-020-0068-6
The current state of the art and future trends in RAS-targeted cancer therapies.
Punekar SR, Velcheti V, Neel BG, Wong KK. · · 2022 · cited 382× · PMID 36028717 · DOI 10.1038/s41571-022-00671-9
Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y, Tao L, Qiu J, Xu J, et al · · 2024 · cited 379× · PMID 38763973 · DOI 10.1038/s41392-024-01823-2
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.
Zhu G, Pei L, Xia H, Tang Q, et al · · 2021 · cited 342× · PMID 34742312 · DOI 10.1186/s12943-021-01441-4
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.
Hofmann MH, Gerlach D, Misale S, Petronczki M, et al · · 2022 · cited 247× · PMID 35046095 · DOI 10.1158/2159-8290.cd-21-1331
Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.
Xie X, Yu T, Li X, Zhang N, et al · · 2023 · cited 246× · PMID 37669923 · DOI 10.1038/s41392-023-01589-z
Emerging strategies to target RAS signaling in human cancer therapy.
Chen K, Zhang Y, Qian L, Wang P. · · 2021 · cited 164× · PMID 34301278 · DOI 10.1186/s13045-021-01127-w
Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers.
Dillon M, Lopez A, Lin E, Sales D, et al · · 2021 · cited 99× · PMID 34680208 · DOI 10.3390/cancers13205059

Verify or expand the search:

Other trials of RMC-4630

Trials testing the same drug.

NCT04916236 — Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers · Phase 1 · terminated
NCT05054725 — Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Th · Phase 2 · completed
NCT04185883 — Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) · Phase 1 · active not recruiting
NCT03989115 — Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC · Phase 1, PHASE2 · completed

Other recruiting trials for Solid Tumors

Currently open trials in the same condition.

NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting

Other Revolution Medicines, Inc. trials

Trials by the same sponsor.

NCT07252232 — Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) · Phase 3 · recruiting
NCT06881784 — Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) · Phase 3 · recruiting
NCT06445062 — Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06040541 — Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors · Phase 1 · recruiting
NCT05462717 — Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03634982 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Revolution Medicines, Inc.
Last refreshed: 1 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03634982.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing